Preparation, Characterization, and In Vitro and In Vivo Evaluation of PEGylated Liposomal Doxorubicin Modified with Different cRGD Peptides

2015 ◽  
pp. 51-68
Author(s):  
Mohamadreza Amin ◽  
Mahmoud Reza Jaafari
Keyword(s):  
Liposomal Doxorubicin ◽  
Pegylated Liposomal Doxorubicin ◽  
In Vivo Evaluation

Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies

Blood ◽  
2005 ◽  
Vol 105 (8) ◽  
pp. 3058-3065 ◽  
Author(s):  
Robert Z. Orlowski ◽  
Peter M. Voorhees ◽  
Reynaldo A. Garcia ◽  
Melissa D. Hall ◽  
Fred J. Kudrik ◽  
...  
Keyword(s):  
Antitumor Activity ◽  
Liposomal Doxorubicin ◽  
Phase 1 ◽  
Pegylated Liposomal Doxorubicin ◽  
Complete Response ◽  
Hematologic Malignancies ◽  
Maximum Tolerated Dose ◽  
Chemotherapeutic Agents

Abstract Proteasome inhibitors, a novel class of chemotherapeutic agents, enhance the antitumor efficacy of anthracyclines in vitro and in vivo. We therefore sought to determine the maximum tolerated dose (MTD) and dose-limiting toxicities of bortezomib and pegylated liposomal doxorubicin (PegLD). Bortezomib was given on days 1, 4, 8, and 11 from 0.90 to 1.50 mg/m2 and PegLD on day 4 at 30 mg/m2 to 42 patients with advanced hematologic malignancies. Grade 3 or 4 toxicities in at least 10% of patients included thrombocytopenia, lymphopenia, neutropenia, fatigue, pneumonia, peripheral neuropathy, febrile neutropenia, and diarrhea. The MTD based on cycle 1 was 1.50 and 30 mg/m2 of bortezomib and PegLD, respectively. However, due to frequent dose reductions and delays at this level, 1.30 and 30 mg/m2 are recommended for further study. Pharmacokinetic and pharmacodynamic studies did not find significant drug interactions between these agents. Antitumor activity was seen against multiple myeloma, with 8 of 22 evaluable patients having a complete response (CR) or near-CR, including several with anthracycline-refractory disease, and another 8 having partial responses (PRs). One patient with relapsed/refractory T-cell non-Hodgkin lymphoma (NHL) achieved a CR, whereas 2 patients each with acute myeloid leukemia and B-cell NHL had PRs. Bortezomib/PegLD was safely administered in this study with promising antitumor activity, supporting further testing of this regimen.

scholarly journals Preparation and Characterization of Hypoxia Sensitive Cationic Liposomal Doxorubicin and Evaluation Its Anti-tumor Activity in Mice Bearing C26 Tumors

2021 ◽  
Author(s):  
Mohammad Mashreghi ◽  
Mahdi Faal Maleki ◽  
Anis Askarizadeh ◽  
Helaleh Farshchi ◽  
Leila Farhoudi ◽  
...  
Keyword(s):  
Liposomal Doxorubicin ◽  
Pegylated Liposomal Doxorubicin ◽  
Tumor Model ◽  
Cationic Liposome ◽  
Cost Effective ◽  
Hypoxic Condition ◽  
Hypoxic Conditions ◽  
Cytotoxicity Studies

Abstract The goal of this study was to prepare cationic nanoliposomal doxorubicin in which PEG molecule attached to the liposome via a hypoxia-sensitive azo linker. The cost-effective hypoxia-sensitive molecule (HSM) was synthesized composing of C18H37 lipophilic tail, azo-linker, and PEG2000 hydrophilic molecule. The NMR and FTIR were employed to characterize the HSM. Then, this compound was post-inserted into the cationic liposome (Cat-lip), and PEG-Azo-Cat-lip was prepared and characterized using DLS. In vitro release and cytotoxicity studies were performed in normoxic and hypoxic conditions. In vivo biodistribution and anti-tumor activities of the formulations were studied on mice bearing C-26 colon carcinoma tumor model and compared with PEGylated liposomal doxorubicin (Caelyx®). Besides, the histological test confirmed the formulation biosafety on healthy mice. The results of NMR and FTIR indicated the synthesis of HSM. The decrease in the zeta-potential of formulation from +18.4 mV for Cat-lip to +6.1 mV along with the increase in the size of the PEG-Azo-Cat-lip indicated the successful post-insertion of HSM. The release study showed that PEGylation results in the more stable PEG-Azo-Cat-lip compared to the Cat-lip. The increased cytotoxicity of the PEG-Azo-Cat-lip in the hypoxic condition also indicated the cleavage of the azo-linker in the hypoxic environment. In vivo biodistribution using animal imaging has shown higher tumor accumulation of the PEG-Azo-Cat-lip than Cat-lip during the 120 h of the study. The results of anti-tumor activities and biosafety of the formulations also showed the higher efficiency of the PEG-Azo-Cat-lip compared with the Cat-lip. The results of this study, indicated the anti-tumor efficacy of this hypoxia-sensitive which merits further investigation.

In vitro and in vivo evaluation of the anti-inflammatory effects of Arzanol from Helichrysum italicum

Planta Medica ◽  
2010 ◽  
Vol 76 (12) ◽  
Author(s):  
J Bauer ◽  
F Dehm ◽  
A Koeberle ◽  
F Pollastro ◽  
G Appendino ◽  
...  
Keyword(s):  
In Vivo Evaluation ◽  
Anti Inflammatory

Fenofibrate Solid Dispersion for Improving Oral Bioavailability: Preparation, and Characterization and in vivo Evaluation

2020 ◽  
Vol 13 (5) ◽  
pp. 5102-5109
Author(s):  
Venu Madhav K ◽  
Somnath De ◽  
Chandra Shekar Bonagiri ◽  
Sridhar Babu Gummadi
Keyword(s):  
Oral Bioavailability ◽  
Oral Delivery ◽  
Solid Dispersions ◽  
In Vitro Release ◽  
Aqueous Solubility ◽  
Water Soluble ◽  
Scanning Calorimetry ◽  
In Vivo Evaluation

Fenofibrate (FN) is used in the treatment of hypercholesterolemia. It shows poor dissolution and poor oral bioavailability after oral administration due to high liphophilicity and low aqueous solubility. Hence, solid dispersions (SDs) of FN (FN-SDs) were develop that might enhance the dissolution and subsequently oral bioavailability. FN-SDs were prepared by solvent casting method using different carriers (PEG 4000, PEG 6000, β cyclodextrin and HP β cyclodextrin) in different proportions (0.25%, 0.5%, 0.75% and 1% w/v). FN-SDs were evaluated solubility, assay and in vitro release studies for the optimization of SD formulation. Differential scanning calorimetry (DSC), powder X-ray diffraction (PXRD) and scanning electron microscopy (SEM) analysis was performed for crystalline and morphology analysis, respectively. Further, optimized FN-SD formulation evaluated for pharmacokinetic performance in Wistar rats, in vivo in comparison with FN suspension.  From the results, FN-SD3 and FN-SD6 have showed 102.9 ±1.3% and 105.5±3.1% drug release, respectively in 2 h. DSC and PXRD studies revealed that conversion of crystalline to amorphous nature of FN from FT-SD formulation. SEM studies revealed the change in the orientation of FN when incorporated in SDs. The oral bioavailability FN-SD3 and FN-SD6 formulations exhibited 2.5-folds and 3.1-folds improvement when compared to FN suspension as control. Overall, SD of FN could be considered as an alternative dosage form for the enhancement of oral delivery of poorly water-soluble FN.

Sign in / Sign up

Export Citation Format

Share Document